As of September 30, 2025, the Company had $104.0 million of cash, cash equivalents, and investment on hand. Since the end of the third quarter ended September 30, 2025, the Company raised a total of $73.8 million in net proceeds from the issuance of 4,976,510 shares of common stock from an underwritten public offering and ATM sales. The Company believes it has sufficient cash to fund operations into 2028 based on current operating plans and assumptions regarding clinical timelines and planned expenditures.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals reports Q3 EPS ($1.90), consensus ($1.71)
- CRBP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Corbus Pharmaceuticals management to meet virtually with B. Riley
- Corbus Pharmaceuticals Announces $70.5M Public Offering
- Corbus Pharmaceuticals 4.744M share Spot Secondary priced at $13.00